Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 52 min ago
Peer-reviewedCC BY-NC-ND 4.0JHEP Reports

Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: Results from the CheckMate 459 phase III trial

2 more authors
12 affiliations
  1. 1Department of Translational Medicine, Bristol Myers Squibb, Princeton, NJ, USA
  2. 2Department of Translational Bioinformatics, Bristol Myers Squibb, Princeton, NJ, USA
  3. 3Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan
  4. 4Department of Medicine, Geffen School of Medicine, University of California–Los Angeles, Los Angeles, CA, USA
  5. 5Liver Unit and HPB Oncology Area, Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain
  6. 6Department of Immunology and Immunotherapy, Clinica Universidad de Navarra and CIBERONC, Pamplona, Spain
  7. 7University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, USA
  8. 8Department of Medicine, University of Hong Kong, Hong Kong, China
  9. 9Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
  10. 10Centre Hépato-Biliaire, Hôpital Paul Brousse, Assistance Publique Hôpitaux de Paris, Université Saclay and Sorbonne Université, Paris, France
  11. 11Oncology Clinical Development, Bristol Myers Squibb, Princeton, NJ, USA
  12. 12UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

Abstract

Background & Aims: First-line nivolumab demonstrated a higher objective response rate (ORR) and favorable safety profile vs. sorafenib in advanced HCC in the phase III CheckMate 459 trial; however, no significant improvement in overall survival (OS) was observed. Here, we report exploratory biomarker analyses from CheckMate 459.

Methods: Archival or fresh tumor samples were collected before treatment and subjected to whole-exome sequencing, whole-transcriptome RNA sequencing, immunohistochemistry, and serological testing. Biomarkers were examined for associations with clinical outcomes (ORR by blinded independent central review [BICR] per RECIST v1.1, progression-free survival [PFS] by BICR, and OS).

Results: The minimum follow-up was 33.6 months. In the nivolumab arm, 201, 230, 343, and ≥293 patients were evaluable by whole-exome sequencing, RNA sequencing, immunohistochemistry, and serology, respectively; 199, 239, 334, and ≥279 patients were evaluable in the sorafenib arm, respectively. Baseline tumor mutational burden was not predictive of survival with nivolumab. OS with sorafenib was improved in patients with mutated vs. wild-type Wnt/β-catenin pathway; consequently, OS was improved with nivolumab vs. sorafenib in patients with unaltered Wnt/β-catenin pathway (hazard ratio [HR] 0.66; 95% CI 0.47-0.91). High T-cell inflammation gene signature score and tumors with high programmed death ligand 1 levels (combined positive score ≥10) were associated with improved OS with nivolumab vs. sorafenib (HR 0.68; 95% CI 0.47-0.98 and HR 0.55; 95% CI 0.33-0.93, respectively); PFS and ORR were also improved. Among circulating blood biomarkers, high interferon-γ, low pro-collagen 11, and low frequency of granulocytic myeloid-derived suppressor cells were associated with improved nivolumab efficacy vs. sorafenib.

Conclusions: These exploratory analyses from CheckMate 459 identified several candidate biomarkers that may be associated with the efficacy of first-line nivolumab vs. sorafenib and support further studies to identify patients with advanced HCC who may benefit from programmed death 1 inhibition.

Impact and implications: Nivolumab demonstrated a higher objective response rate and favorable safety profile as first-line treatment compared with sorafenib for patients with advanced HCC in the CheckMate 459 trial, yet did not show a significant improvement in overall survival. The exploratory analyses presented here have identified several candidate biomarkers that may be associated with the efficacy of nivolumab vs. sorafenib in the first-line setting. These findings support additional studies to identify patients who may benefit from programmed death 1 inhibition.

Clinical trial number: NCT02576509.

Related

  1. Factors Associated with Variceal bleeding in patients with advanced hepatocellular carcinoma treated with Sorafenib or Regorafenib
    Mohamed Salaheldin, Mohamed Fouad, Heba Aly +3
    Ain Shams Medical JournalPeer-reviewedCC BYFull textGeneral medicineDOAJ
  2. Cost-effectiveness analysis of penpulimab plus anlotinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma
    Zhiwei Zheng, Lisheng Huang, Yuling Zhang +2
    ImmunotherapyPeer-reviewedLicence not statedFull textGeneral medicinePMC
  3. Identification of hepatitis B virus-associated membrane proteins as prognostic biomarkers for hepatocellular carcinoma based on retrospective analysis of integrated membrane proteomics
    Zichen Liu, Jiaming Wan, Guoli Deng +5
    Translational cancer researchPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  4. USP54 regulates RIPK1 protein abundance via deubiquitination in acquired sorafenib resistance in hepatocellular carcinoma
    Jiayu Huang, Chen Sun, Yitao Huang +4
    Scientific ReportsPeer-reviewedCC BY 4.0Full textGeneral medicineNatureCrossrefDOAJ
  5. Effectiveness of lenvatinib versus sorafenib as first- or second-line therapy in hepatocellular carcinoma: insights from real-life data, systematic review, and meta-analysis
    Rosanna Villani, Elisabetta Cornacchia, Nicolò Maria Sguera +4
    Gastroenterology ReportPeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMC
BibTeX
@article{neely2026biomarkers,
  title = {{Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: Results from the CheckMate 459 phase III trial}},
  author = {Jaclyn Neely and Jin Yao and Masatoshi Kudo and Richard S. Finn and Bruno Sangro and Ignacio Melero and Anthony B. El-Khoueiry and Thomas Yau and James J. Harding and Olivier Rosmorduc and Marina Tschaika and Ruslan Novosiadly and Amanda Cruz and Robin Kate Kelley},
  journal = {JHEP Reports},
  year = {2026},
  month = sep,
  doi = {10.1016/j.jhepr.2026.102038},
  url = {https://doi.org/10.1016/j.jhepr.2026.102038},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: Results from the CheckMate 459 phase III trial
AU  - Jaclyn Neely
AU  - Jin Yao
AU  - Masatoshi Kudo
AU  - Richard S. Finn
AU  - Bruno Sangro
AU  - Ignacio Melero
AU  - Anthony B. El-Khoueiry
AU  - Thomas Yau
AU  - James J. Harding
AU  - Olivier Rosmorduc
AU  - Marina Tschaika
AU  - Ruslan Novosiadly
AU  - Amanda Cruz
AU  - Robin Kate Kelley
PY  - 2026
DA  - 2026/09/19
JO  - JHEP Reports
DO  - 10.1016/j.jhepr.2026.102038
UR  - https://doi.org/10.1016/j.jhepr.2026.102038
AB  - Background & Aims: First-line nivolumab demonstrated a higher objective response rate (ORR) and favorable safety profile vs. sorafenib in advanced HCC in the phase III CheckMate 459 trial; however, no significant improvement in overall survival (OS) was observed. Here, we report exploratory biomarker analyses from CheckMate 459.  Methods: Archival or fresh tumor samples were collected before treatment and subjected to whole-exome sequencing, whole-transcriptome RNA sequencing, immunohistochemistry, and serological testing. Biomarkers were examined for associations with clinical outcomes (ORR by blinded independent central review [BICR] per RECIST v1.1, progression-free survival [PFS] by BICR, and OS).  Results: The minimum follow-up was 33.6 months. In the nivolumab arm, 201, 230, 343, and ≥293 patients were evaluable by whole-exome sequencing, RNA sequencing, immunohistochemistry, and serology, respectively; 199, 239, 334, and ≥279 patients were evaluable in the sorafenib arm, respectively. Baseline tumor mutational burden was not predictive of survival with nivolumab. OS with sorafenib was improved in patients with mutated vs. wild-type Wnt/β-catenin pathway; consequently, OS was improved with nivolumab vs. sorafenib in patients with unaltered Wnt/β-catenin pathway (hazard ratio [HR] 0.66; 95% CI 0.47-0.91). High T-cell inflammation gene signature score and tumors with high programmed death ligand 1 levels (combined positive score ≥10) were associated with improved OS with nivolumab vs. sorafenib (HR 0.68; 95% CI 0.47-0.98 and HR 0.55; 95% CI 0.33-0.93, respectively); PFS and ORR were also improved. Among circulating blood biomarkers, high interferon-γ, low pro-collagen 11, and low frequency of granulocytic myeloid-derived suppressor cells were associated with improved nivolumab efficacy vs. sorafenib.  Conclusions: These exploratory analyses from CheckMate 459 identified several candidate biomarkers that may be associated with the efficacy of first-line nivolumab vs. sorafenib and support further studies to identify patients with advanced HCC who may benefit from programmed death 1 inhibition.  Impact and implications: Nivolumab demonstrated a higher objective response rate and favorable safety profile as first-line treatment compared with sorafenib for patients with advanced HCC in the CheckMate 459 trial, yet did not show a significant improvement in overall survival. The exploratory analyses presented here have identified several candidate biomarkers that may be associated with the efficacy of nivolumab vs. sorafenib in the first-line setting. These findings support additional studies to identify patients who may benefit from programmed death 1 inhibition.  Clinical trial number: NCT02576509.
SN  - 2589-5559
ER  -